Triumvira Immunologics
Latest round
- Series A
Last raised
- Mar 2022
Total raised
- $64M
Investors
- 9
About Triumvira Immunologics
Triumvira Immunologics, Inc.Founded in 2015 in Austin, US, Triumvira Immunologics specializes in immunotherapy solutions.Triumvira Immunologics specializes in advanced immunotherapy solutions utilizing their proprietary T cell Antigen Coupler (TAC) technology. This innovative platform enhances the immune response by enabling T cells to recognize and target a variety of cancer antigens, thereby facilitating the destruction of both liquid and solid tumors. The TAC technology operates through natural T cell activation and signaling mechanisms, resulting in controlled and effective anti-tumor responses.2 in advanced solid tumors.Triumvira Immunologics generates revenue through partnerships and collaborations with healthcare providers, research institutions, and pharmaceutical firms focused on oncology. The company's transaction structure is primarily based on B2B arrangements, where therapeutic candidates are developed and tested in clinical trials, potentially leading to commercialization upon successful outcomes. Revenue streams may arise from licensing agreements, where Triumvira licenses its proprietary TAC technology to partners for further development and marketing.2, represents a significant aspect of the company's offerings, with its development geared towards addressing the unmet needs of patients with solid tumors. The company is focused on expanding its market presence in North America and Europe, aiming to meet the growing demand for innovative cancer therapies.2 and other candidates, reinforcing Triumvira's commitment to addressing significant unmet medical needs in oncology.
Who invested in Triumvira Immunologics
9 investors across 2 rounds
See all investors in Triumvira Immunologics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Triumvira Immunologics
Who invested in Triumvira Immunologics?
Triumvira Immunologics has 9 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Triumvira Immunologics raised?
Triumvira Immunologics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Triumvira Immunologics last raise money?
Triumvira Immunologics's most recent round on record is a Series A, in Mar 2022.
What does Triumvira Immunologics do?
Triumvira Immunologics is a biotechnology company.
Where is Triumvira Immunologics headquartered?
Triumvira Immunologics is headquartered in Austin, US.
Which VCs invest in companies like Triumvira Immunologics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Triumvira Immunologics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Triumvira Immunologics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.